A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 ... Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and R... Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug ...STOCK Quote
NASDAQ: AERI
$10.61USD
Oct 30, 4:00 PM ET
VOLUME
826,695
DAY LOW/HIGH
$10.30/$10.91
52 - WEEK LOW/HIGH
$9.01/$26.26
